Quick Answer
Krystal Biotech, Inc. reported Cash and Equivalents of $496.30 million for fiscal year 2025.
Krystal Biotech, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $496.30M | +43.9% |
| 2024 | $344.87M | -3.8% |
| 2023 | $358.33M | +121.3% |
| 2022 | $161.90M | -52.6% |
| 2021 | $341.25M | +27.2% |
| 2020 | $268.27M | +43.1% |
| 2019 | $187.51M | +80.9% |
| 2018 | $103.67M | +109.1% |
| 2017 | $49.59M | +2478.8% |
| 2016 | $1.92M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $392.60M | +5.0% | +11.0% |
| June 30, 2025 | $353.83M | +2.3% | +14.6% |
| March 31, 2025 | $308.77M | -14.0% | -10.5% |
| December 31, 2024 | $344.87M | -3.8% | -7.8% |
| September 30, 2024 | $373.97M | +0.2% | +8.1% |
| June 30, 2024 | $345.79M | +25.3% | -3.7% |
| March 31, 2024 | $359.01M | +155.1% | +0.2% |
| December 31, 2023 | $358.33M | +121.3% | -4.0% |
- Krystal Biotech, Inc. showed an increase of +43.9% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2016–2025 period, Krystal Biotech, Inc.’s cash and equivalents has grown by 25708.8% (from $1.92 million to $496.30 million).
- The most recent figure is from Krystal Biotech, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 17, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: